Forget a Cash ISA! I’d invest in these 2 FTSE 100 shares today to make a million

I think these two FTSE 100 (INDEXFTSE:UKX) shares could offer high returns due, in part, to their low valuations.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Opening a Cash ISA could lead to long-term disappointment. Even the best rates available are lower than inflation, which means the spending power of your capital may fall over the long run.

By contrast, the FTSE 100 offers a relatively high dividend yield of over 4%. The index could also deliver impressive levels of capital growth, with its track record showing it’s likely to overcome the near-term risks currently faced.

As such, now could be the right time to invest in these two FTSE 100 stocks. They could offer high returns that ultimately improve your prospects of making a million in the long run.

GSK

The prospects for pharmaceutical companies, such as GSK (LSE: GSK), could improve over the coming years. A number of factors, such as an ageing world population and increasing urbanisation, may contribute to increasing demand for the company’s products. This could lead to a potential tailwind for the business as it embarks on a more focused strategy that has seen it dispose of a number of major consumer healthcare brands.

In addition, GSK may become a more popular stock among investors due to its relatively low correlation with the wider economy. At a time when investors are fearful about events such as Brexit, US political risks, and a global trade war, healthcare companies may seem to be a resilient means of generating growth.

With a price-to-earnings (P/E) ratio of 14.5, the company appears to offer good value for money compared to its sector peers. Its dividend yield of 4.6% is roughly in line with the wider index, but could grow at a fast pace due to favourable operating conditions over the coming years.

Compass Group

The financial performance of support services company Compass Group (LSE: CPG) over recent years has been highly impressive, as well as consistent. It has recorded an annualised rise in net profit of over 10% in the last five years, delivering growth in every year during the period.

Its consistent performance could attract investors who are looking for increasingly dependable returns during a period where global economic risks are heightened. Compass Group is forecast to record a rise in net profit of 9% in the current year, which suggests that its overall strategy is working well.

The company continues to make bolt-on acquisitions that could enhance its financial outlook. Its financial position suggests that there’s scope for it to engage in further M&A activity, while its recent strong performance in the US could continue as it seeks to widen margins in many of its key markets.

From a long-term risk/reward perspective, Compass Group appears to have strong appeal. It could offer a mix between impressive growth and relatively resilient returns that increases your chances of generating a seven-figure portfolio.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Compass Group. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Here are the 10 highest-FTSE growth stocks

The FTSE might not have a reputation for innovation and growth, but these top 10 stocks have produced incredible returns…

Read more »

Investing Articles

What on earth is going on with the S&P 500?

Our writer looks at why the S&P 500 has been volatile in December, as well as highlighting a FTSE 100…

Read more »

Stacks of coins
Investing Articles

1 penny stock mistake to avoid in 2025

Ben McPoland explores a rookie error common to penny stock investing, and also highlights a 19p small-cap that looks like…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

What can Warren Buffett teach an investor with £1,000?

Although Warren Buffett’s a billionaire, his investing lessons can be applied to far more modest portfolios. Our writer explains some…

Read more »

Light bulb with growing tree.
Investing Articles

Down 43%, could the ITM share price start rising again in 2025?

After news of the latest sales deal being inked, our writer revisits the ITM share price and considers if the…

Read more »

Runner standing at the starting point with 2025 year for starting in new year 2025 to achieve business planing and success concept.
Investing Articles

Is 2024’s biggest FTSE faller now the best share to buy for 2025?

Harvey Jones thought this FTSE 100 growth stock was the best share to buy for 2024, but was wrong. Yet…

Read more »

New year resolutions 2025 on desk. 2025 resolutions list with notebook, coffee cup on table.
Investing Articles

Legal & General has huge passive income potential with a forecast yield of almost 10% in 2025!

Harvey Jones got a fabulous rate of passive income from this top FTSE 100 dividend stock in 2024, and believes…

Read more »

Investing Articles

This stock market dip is my chance to buy cheap FTSE shares for 2025!

Harvey Jones was looking forward to a Santa Rally in December, but it looks like we're not going to get…

Read more »